🚨 Hot Job Alert! 🚨 We’re #hiring a Senior Medical Director, Drug Safety and Pharmacovigilance! This #remote role is critical to our Drug Safety team, led by Doreen G., which focuses on analyzing safety data, investigating safety signals, risk management, and providing medical safety review of our products. Interested? Find out more --> https://lnkd.in/gTukEurQ #GrowWithUs #biotechnology #biotech
Dianthus Therapeutics, Inc.
Biotechnology Research
New York City, New York 5,193 followers
Unlocking the full potential of complement therapeutics through the power of selectivity.
About us
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
- Website
-
https://dianthustx.com
External link for Dianthus Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New York City, New York
- Type
- Public Company
Locations
-
Primary
7 Times Square, Floor 43
New York City, New York, US
-
203 Crescent St
Building 4, Suite 205
Waltham, Massachusetts 02453, US
Employees at Dianthus Therapeutics, Inc.
-
Doreen G.
Medical Affairs | Drug Safety & Pharmacovigilance | Rare Disease | Oncology | Cell Therapies
-
Nir Grabie
Science Leadership in Translational Science, Immune-Modulation and I/O R&D
-
Nate Inkrote
Accomplished Product Development & Sales Executive | Leading Medical Device Innovations for Enhanced Healthcare Solutions
-
Jonathan Violin
Venture Partner
Updates
-
Judson Taylor and L. Wayne Schultz hosted last month’s CMC team meeting at our New York office. The team had the chance to connect in-person, share ideas and plans for the next few months, and welcomed a new member to the team! #biotech #GrowWithUs #biotechnology
-
Conference season continues with tomorrow’s Stifel 2024 Inflammation and Immunology Summit! Click below to hear from our CEO Marino Garcia via webcast: https://lnkd.in/g9Bqa8Ve
Stifel 2024 Virtual Immunology and Inflammation Summit | Dianthus Therapeutics
investor.dianthustx.com
-
Catch us tomorrow at the Cantor Fitzgerald 2024 Global Health Conference to hear the latest from our CEO Marino Garcia. Unable to join in-person? Join the webcast here: https://lnkd.in/gD7XmUFM #CantorHCC
Cantor 2024 Global Healthcare Conference | Dianthus Therapeutics
investor.dianthustx.com
-
Today marks a monumental day for Dianthus: it’s officially been one year since we began publicly trading on Nasdaq under the ticker DNTH! Some highlights from the last 12 months include: • Successful completion of our Phase 1 study of DNTH103 in healthy volunteers • Initiation of our Phase 2 MaGic trial of DNTH103 for patients with gMG and Phase 2 MoMeNtum trial of DNTH103 for patients with MMN • Presentations of DNTH103 data at multiple industry conferences, starting with the American Academy of Neurology (AAN) Annual Meeting • And completion of a successful $230M PIPE financing in January Cheers to a great first year as a public company!
-
Find our team at the following conferences this September! Hear CEO Marino Garcia present our latest business updates at the Baird 2024 Global Health Conference, the 2024 Cantor Fitzgerald Global Health Conference, and the Stifel Institutional 2024 Virtual Immunology and Inflammation Summit. #biotechnology #biotech #innovation
-
Today, we reported our Q2 2024 financial results and highlighted recent business achievements. “The second quarter of 2024 highlighted the Dianthus team’s continued focus on execution and operational excellence as we advance our clinical programs for DNTH103 in generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy,” said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. “We believe DNTH103 may be a potentially best-in-class, potent classical complement pathway inhibitor with infrequent, subcutaneous self-administration and a differentiated safety profile across our three initial indications of gMG, MMN and CIDP. We continue to be confident in the pipeline-in-a-product potential of DNTH103 across multiple autoimmune diseases, supported by our proof-of-concept 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 data presented at EAN and recent competitor clinical data that further validate targeting the classical pathway and active C1s.” https://lnkd.in/eSkS37Q4
-
🚨 Hot Job Alert! 🚨 We are #hiring a Director, Drug Safety Operations. You will work closely with Doreen G. to oversee and develop safety operations activities. You will partner with internal and external global teams supporting our three clinical programs, as we work together on the development of next-generation antibody #ComplementTherapeutics. To join us, learn more and #apply here: https://lnkd.in/euYZRz-W
-
🚨 Hot Job Alert! 🚨 We are #hiring a Senior Medical Director, Drug Safety and Pharmacovigilance. You will be leading the analysis of safety data, identifying, detecting and investigating safety signals, as well as evaluating and proactively managing risk, as we advance the development of next-generation antibody #ComplementTherapeutics. To join us, learn more and #apply here: https://lnkd.in/etmY5eEe
-
We asked our team how they’d describe Dianthus, take a look at some of their responses! For the second year in a row, the top 3 words were Open, Collaborative, and Supportive, with two new additions, Motivated and Ambitious! As our company evolves, we aim to continue cultivating an environment where our employees thrive and #GrowTogether. Visit dianthustx.com/careers to learn more about our mission, culture, and opportunities to join our team! #biotech #teamwork #employeeengagement